Twist Bioscience Boosts Workforce with 147,800 Equity Awards to New Hires

Twist Bioscience Expands Workforce with New Equity Awards

Twist Bioscience Corporation, a prominent player in synthetic biology based in South San Francisco, is taking significant steps to enhance its workforce. The company announces the grant of 147,800 equity awards to incentivize 43 newly hired employees, marking an important initiative to attract top talent in a competitive industry. This move aligns with Nasdaq regulations and reflects Twist's commitment to fostering innovation through a robust team. Among the new hires, Colby Souders, appointed as Vice President, receives a substantial portion of the awards, including 110,300 restricted stock units (RSUs) and up to 37,500 performance stock units (PSUs).

The structure of the equity awards is designed to promote long-term commitment and performance among employees. The RSUs will vest over a 48-month period, with an initial 25% vesting on the first anniversary of each employee's start date, followed by quarterly vesting. This approach ensures that employees remain engaged and motivated, driving their contributions to the company's goals. Meanwhile, the PSUs are tied to specific performance metrics set by the Company's Compensation Committee for fiscal years 2024 to 2026, with potential earnings ranging from 80% to 150% of the target. This performance-based component encourages a results-oriented culture within Twist Bioscience.

This strategic move to bolster its workforce aligns seamlessly with Twist's mission to revolutionize the engineering of biology. By leveraging its proprietary DNA synthesis platform, which utilizes silicon chips to produce synthetic DNA, the company aims to expand its market presence and influence across diverse sectors, including healthcare, agriculture, and industrial chemicals. The Inducement Equity Incentive Plan not only aids in attracting skilled professionals but also reflects Twist's dedication to harnessing cutting-edge technology to manufacture a wide range of synthetic DNA-based products, further solidifying its position as a leader in the rapidly evolving synthetic biology field.

In addition to the new equity awards, Twist Bioscience continues to explore groundbreaking applications of its technology. The company is actively engaged in research and development initiatives aimed at digital data storage in DNA and biologics drug discovery. These innovations not only enhance its product portfolio but also contribute to the broader field of genomics, positioning Twist as a key player in the future of synthetic biology.

As Twist Bioscience expands its workforce and continues to innovate, the company is well-positioned to lead the charge in transforming synthetic biology and genomics, driving advancements that have the potential to impact various industries significantly.